Nabriva Therapeutics plc (NBRV) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Revenue Growth NBRV has had growing revenue for the last 2 years
Net Income Growth NBRV has had growing net income for the last 4 years
Price to Book (PBV) Ratio Undervalued price-to-book. NBRV stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER) NBRV equity is higher than it's debt.
Revenue NBRV has positive revenue for last 4 years

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Net Income NBRV never has positive net income for 2 years.
Dividend Yield NBRV has low dividend yield (0%).
Return of Assets NBRV has low return of asset (-98.4%).
Return of Equity NBRV has low return of equity (-120.02%).
Return of Invested Capital NBRV has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-59,557,000 USD

Dividend

Financial Ratios

CEO

CEO Name

Mr. Theodore Schroeder

Management

About Nabriva Therapeutics plc

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Additional Information

Company name

Nabriva Therapeutics plc

Symbol

NASDAQ:NBRV

Exchange

NASDAQ Global Select

Industry

Biotechnology

Sector

Healthcare

Address

56 Fitzwilliam Square North
DUBLIN

IE
1

Website

https://www.nabriva.com